A 72-year-old woman with diabetes mellitus type 2 is admitted to the ICU on day 5 of mechanical ventilation following elective abdominal surgery. She develops fever (39.2°C), purulent endotracheal secretions, and a new infiltrate on chest X-ray in the right lower lobe. Blood cultures are negative. Sputum culture grows Acinetobacter baumannii resistant to all beta-lactams and fluoroquinolones. What is the most appropriate antimicrobial therapy?

Explanation

## Clinical Context: Multidrug-Resistant (MDR) Acinetobacter baumannii HAP This patient has **hospital-acquired pneumonia (HAP)** with a multidrug-resistant (MDR) gram-negative pathogen: - Ventilator-associated pneumonia (VAP) on day 5 of mechanical ventilation - Acinetobacter baumannii (gram-negative coccobacillus) - Resistance to beta-lactams (including carbapenems) and fluoroquinolones **Key Point:** MDR A. baumannii with carbapenem resistance is a major nosocomial pathogen. Treatment options are severely limited; colistin is often the only reliably active agent. ## Antibiotic Options for Carbapenem-Resistant A. baumannii | Agent | Activity vs. Carbapenem-Resistant A. baumannii | Notes | |-------|-----------------------------------------------|-------| | Meropenem | Ineffective (resistant) | Not appropriate for this isolate | | **Colistin** | **Excellent** | **First-line for MDR/XDR A. baumannii** | | Ceftazidime-avibactam | Variable (less reliable) | Newer agent; activity against some carbapenem-resistant gram-negatives, but A. baumannii resistance common | | Tigecycline | Moderate | Broad-spectrum; often reserved for polymicrobial infections; slower bactericidal activity | **High-Yield:** Colistin (polymyxin E) is the gold standard for carbapenem-resistant A. baumannii HAP/VAP. Dosing: 2–3 million units IV Q8H (or 50,000–75,000 units/kg/day divided Q8H). Inhaled colistin can be added for VAP to achieve high lung concentrations. ## Why Colistin Is the Answer 1. **Resistance pattern**: A. baumannii in this case is resistant to carbapenems (meropenem ineffective) and fluoroquinolones. 2. **Colistin activity**: Retained activity against virtually all A. baumannii strains, including carbapenem-resistant and XDR (extensively drug-resistant) isolates. 3. **Clinical evidence**: Colistin is the standard of care for carbapenem-resistant A. baumannii HAP/VAP in ICU settings. 4. **Combination therapy**: Often combined with rifampin or other agents to reduce resistance emergence. **Clinical Pearl:** Colistin nephrotoxicity and neurotoxicity are concerns, but in the setting of life-threatening MDR A. baumannii infection, the benefit outweighs the risk. Renal function and neurological status must be monitored. ## Why Not the Others? - **Meropenem**: The isolate is resistant to carbapenems; meropenem will be ineffective and lead to clinical failure. - **Ceftazidime-avibactam**: While this newer agent has activity against some carbapenem-resistant gram-negatives, A. baumannii frequently produces resistance mechanisms (e.g., OXA-23 carbapenemase) that are not reliably inhibited by avibactam. It is not the first-line choice for this pathogen. - **Tigecycline**: Broad-spectrum tetracycline with activity against A. baumannii, but slower bactericidal kinetics and lower lung penetration compared to colistin. Reserved for polymicrobial infections or when colistin is contraindicated. [cite:Harrison 21e Ch 297]